UPC — Universe Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $2.95m
- -$36.60m
- $23.02m
- 72
- 90
- 19
- 64
Annual cashflow statement for Universe Pharmaceuticals, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | C2022 September 30th | C2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 7.56 | 11.3 | -7.91 | -6.58 | -8.73 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.023 | -0.229 | 0.017 | -0.049 | 0.186 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.87 | -12.9 | 6.6 | 6.62 | -2.06 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 6.12 | -2.06 | -1.3 | 1.12 | -9.51 |
| Capital Expenditures | -0.052 | -0.445 | -0.094 | -0.044 | -0.326 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | -26.6 | -3.81 | 0 | -0.036 |
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.052 | -27.1 | -3.91 | -0.044 | -0.361 |
| Financing Cash Flow Items | -0.441 | -2.79 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.47 | 26.6 | 3.32 | -1.39 | 34 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 6.88 | -1.98 | -2.37 | -0.426 | 24.2 |